Brief: Astrazeneca Pharma India Receives Permission To Import Durvalumab For Additional Indication
28/02/2025 11:32
Feb 28 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS: RECEIVES PERMISSION TO IMPORT DURVALUMAB FOR ADDITIONAL INDICATION GETS PERMISSION FROM CENTRAL DRUGS STANDARD CONTROL ORGANISATION, INDIA Source text: ID:nNSE3QqT8W Further company coverage: ASTR.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Astrazeneca Pharma India
See all newsBrief: Astrazeneca Pharma Gets Permission To Import For Sale Of Trastuzumab Deruxtecan
India's Astrazeneca Pharma logs worst slide in two months on quarterly profit drop
Brief: Astrazeneca Pharma India March-Quarter PAT 448.8 Million Rupees
Brief: Astrazeneca Pharma India Recommends Dividend Of 36 Rupees Per Equity Share For Fy2025-26
Brief: Astrazeneca Pharma India Receives Permission To Import Durvalumab (Imfinzi) For Additional Indication